Evolus to Participate in the 7th Annual Truist Securities Life Sciences Summit
NEWPORT BEACH, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 7th Annual Truist Securities Life Sciences Summit.
|Event:||7th Annual Truist Securities Life Sciences Summit|
|Format:||Fireside Chat & 1x1 Meetings|
|Date:||Wednesday, May 5, 2021|
|Time:||3:30pm – 4:10pm ET|
|Location:||Evolus Live Fireside Chat|
An audio webcast of Evolus’ fireside chat will be available on the investor relations section of Evolus’ website at investors.evolus.com. Replay of the webcast will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
The Ruth Group
Senior Vice President